Ts-1 (Teysuno, S-1)
Other Medications · Approved since 2010
Description
TS-1 (tegafur/gimeracil/oteracil) is an oral fluoropyrimidine-based chemotherapy agent that combines three active components to enhance antitumor efficacy while reducing toxicity. It is used as both first-line and second-line treatment for advanced and metastatic colorectal cancer, often in combination with other agents such as irinotecan or oxaliplatin. The formulation provides sustained 5-fluorouracil levels through tegafur while gimeracil inhibits 5-FU degradation and oteracil reduces gastrointestinal toxicity.
Mechanism of Action
TS-1 works through its primary component tegafur, which is converted to 5-fluorouracil (5-FU) in tumor tissues, where it inhibits thymidylate synthase and disrupts DNA synthesis and repair. Gimeracil inhibits dihydropyrimidine dehydrogenase (DPD), the enzyme responsible for 5-FU catabolism, thereby maintaining therapeutic drug levels. Oteracil selectively inhibits 5-FU phosphorylation in the gastrointestinal tract, reducing dose-limiting diarrhea and mucositis.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Teysuno, S-1 |
| Category | Other Medications |
 Status | FDA Approved |
| Administration | Oral |
| Year Approved | 2010 |
| Clinical Trials | 4 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.